Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in non-metastatic muscle invasive bladder cancer
NCT03498196Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in Muscle Invasive Bladder Cancer (MIBC), sponsored by Baylor College of Medicine. Started Dec 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT03498196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498196.